Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954

被引:61
|
作者
Race, Paul R.
Lovering, Andrew L.
White, Scott A.
Grove, Jane I.
Searle, Peter F.
Wrighton, Christopher W.
Hyde, Eva I. [1 ]
机构
[1] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
[3] ML Labs, Keele ST5 5SP, Staffs, England
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会;
关键词
nitroreductase; CB1954; protein engineering; X-ray structure; gene therapy;
D O I
10.1016/j.jmb.2007.02.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme-prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this systeni. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and FIN affect the interactions with nicotinic acid. The structure of double mutant N71S/FI24K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:481 / 492
页数:12
相关论文
共 28 条
  • [1] Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954
    Guise, CP
    Grove, JI
    Lovering, AL
    Race, PR
    Wrighton, CJ
    White, SA
    Hyde, EI
    Searle, PF
    JOURNAL OF GENE MEDICINE, 2004, 6 (09): : S32 - S32
  • [2] Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954
    Grove, JI
    Lovering, AL
    Guise, C
    Race, PR
    Wrighton, CJ
    White, SA
    Hyde, EI
    Searle, PF
    CANCER RESEARCH, 2003, 63 (17) : 5532 - 5537
  • [3] Structural basis of Escherichia coli nitroreductase NfsB triple mutants engineered for improved activity and regioselectivity toward the prodrug CB1954
    Bai, Jing
    Yang, Jun
    Zhou, Yong
    Yang, Qing
    PROCESS BIOCHEMISTRY, 2015, 50 (11) : 1760 - 1766
  • [4] Mechanism of CB1954 reduction by Escherichia coli nitroreductase
    Christofferson, Andrew
    Wilkie, John
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2009, 37 : 413 - 418
  • [5] Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo
    White, C. L.
    Menghistu, T.
    Twigger, K. R.
    Searle, P. F.
    Bhide, S. A.
    Vile, R. G.
    Melcher, A. A.
    Pandha, H. S.
    Harrington, K. J.
    GENE THERAPY, 2008, 15 (06) : 424 - 433
  • [6] Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo
    C L White
    T Menghistu
    K R Twigger
    P F Searle
    S A Bhide
    R G Vile
    A A Melcher
    H S Pandha
    K J Harrington
    Gene Therapy, 2008, 15 : 424 - 433
  • [7] E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
    Vass, S. O.
    Jarrom, D.
    Wilson, W. R.
    Hyde, E. I.
    Searle, P. F.
    BRITISH JOURNAL OF CANCER, 2009, 100 (12) : 1903 - 1911
  • [8] E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
    S O Vass
    D Jarrom
    W R Wilson
    E I Hyde
    P F Searle
    British Journal of Cancer, 2009, 100 : 1903 - 1911
  • [9] Steady-State and Stopped-Flow Kinetic Studies of Three Escherichia coli NfsB Mutants with Enhanced Activity for the Prodrug CB1954
    Jarrom, David
    Jaberipour, Mansooreh
    Guise, Christopher P.
    Daff, Simon
    White, Scott A.
    Searle, Peter F.
    Hyde, Eva I.
    BIOCHEMISTRY, 2009, 48 (32) : 7665 - 7672
  • [10] Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954
    Prosser, G. A.
    Copp, J. N.
    Syddall, S. P.
    Williams, E. M.
    Smaill, J. B.
    Wilson, W. R.
    Patterson, A. V.
    Ackerley, D. F.
    BIOCHEMICAL PHARMACOLOGY, 2010, 79 (05) : 678 - 687